© 1993 by Oxford University Press
Journal of the National Cancer Institute, Vol. 85, No. 1, 53-59,
January 6, 1993
© 1993 Oxford University Press
Nuclear Overexpression of p53 Protein in Transitional Cell Bladder Carcinoma: A Marker for Disease Progression
Urology Service, Department of Surgery, Memorial Sloan-Kettering Cancer Center New York, N.Y.
Department of Pathology, Memorial Sloan-Kettering Cancer Center New York, N.Y.
Department of Epidemiology and Biostatistics, Memorial Sloan-Kettering Cancer Center New York, N.Y.
Correspondence to: Victor E. Reuter, Department of Pathology, Memorial Sloan-kettering Cancer Center, 1275 York Ave., New York, NY 10021.
Background: Approximately one third of the patients with superficially infiltrative transitional cell (T1—TNM pathological staging system) bladder carcinoma who are treated with transurethral resection alone have disease progression. Despite precise pathologic staging and grading, clinical outcome in these patients is not predictable. Recent reports reveal that mutations of the p53 tumor suppressor gene (also known as TP53) occur commonly in bladder cancers. Purpose: The aim of this study was to investigate the hypothesis that altered patterns of expression of the protein product(s) of the mutated p53 tumor suppressor gene are associated with tumor progression in patients with T1 bladder cancer. Methods: We examined deparaffinized tumor tissue specimens from transurethral resection in 43 patients with T1 bladder cancer who had not received adjuvant therapy. Nuclear overexpression of p53 protein was detected by immunohistochemical analysis using the mouse monoclonal antibody PAb1801, which stains both wild-type and mutant p53 proteins. The data were then correlated with the following conventional prognostic variables: age, sex, histologic presence of associated carcinoma in situ, and vascular invasion of tumor. Disease progression rates per 100 person-years were calculated. Results: Median follow-up was 119 months. None of the urothelial and stromal cells from normal bladder specimens showed nuclear overexpression of p53 protein, but patients with T1 bladder tumors could be stratified into two groups with different patterns of staining for p53 protein. Eighteen patients (42%) had no more than 20% tumor cells with positive nuclear staining (group A), while the remaining 25 patients (58%) had 20% or more tumor cells with nuclear immunoreactivity (group B). Patients in group B had a significantly lower progression-free interval (p<.001). Disease progression rates were 20.5% per year for group B and 2.5% for group A. Conclusion: These results suggest that T1 bladder cancers exhibiting nuclear overexpression of p53 protein have a higher probability of disease progression. This study also suggests that p53 overexpression is an important prognostic factor in these patients and may be useful in selecting appropriate therapy. Implications: Large prospective studies are needed to confirm these results and to evaluate nuclear overexpression of p53 protein as a prognostic marker in bladder cancer. [J Natl Cancer Inst 85: 53–59, 1993]
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  B. George, R. H. Datar, L. Wu, J. Cai, N. Patten, S. J. Beil, S. Groshen, J. Stein, D. Skinner, P. A. Jones, et al. p53 Gene and Protein Status: The Role of p53 Alterations in Predicting Outcome in Patients With Bladder Cancer J. Clin. Oncol., December 1, 2007; 25(34): 5352 - 5358. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K. Iida, K. Itoh, J. M. Maher, Y. Kumagai, R. Oyasu, Y. Mori, T. Shimazui, H. Akaza, and M. Yamamoto Nrf2 and p53 cooperatively protect against BBN-induced urinary bladder carcinogenesis Carcinogenesis, November 1, 2007; 28(11): 2398 - 2403. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. P. Mitra, R. H. Datar, and R. J. Cote Molecular Pathways in Invasive Bladder Cancer: New Insights Into Mechanisms, Progression, and Target Identification J. Clin. Oncol., December 10, 2006; 24(35): 5552 - 5564. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 F. Maluf, C Cordon-Cardo, D. Verbel, J. Satagopan, M. Boyle, H Herr, and D. Bajorin Assessing interactions between mdm-2, p53, and bcl-2 as prognostic variables in muscle-invasive bladder cancer treated with neo-adjuvant chemotherapy followed by locoregional surgical treatment Ann. Onc., November 1, 2006; 17(11): 1677 - 1686. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 E. Lopez-Knowles, S. Hernandez, M. Kogevinas, J. Lloreta, A. Amoros, A. Tardon, A. Carrato, S. Kishore, C. Serra, N. Malats, et al. The p53 Pathway and Outcome among Patients with T1G3 Bladder Tumors. Clin. Cancer Res., October 15, 2006; 12(20): 6029 - 6036. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. A. Knowles Molecular subtypes of bladder cancer: Jekyll and Hyde or chalk and cheese? Carcinogenesis, March 1, 2006; 27(3): 361 - 373. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A Quintero, J Alvarez-Kindelan, R J Luque, R Gonzalez-Campora, M J Requena, R Montironi, and A Lopez-Beltran Ki-67 MIB1 labelling index and the prognosis of primary TaT1 urothelial cell carcinoma of the bladder J. Clin. Pathol., January 1, 2006; 59(1): 83 - 88. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A.-F. Dekairelle, B. Tombal, J.-P. Cosyns, and J.-L. Gala Assessment of the Transcriptional Activity of p53 Improves the Prediction of Recurrence in Superficial Transitional Cell Carcinoma of the Bladder Clin. Cancer Res., July 1, 2005; 11(13): 4724 - 4732. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. J. Wild, A. Herr, C. Wissmann, R. Stoehr, A. Rosenthal, D. Zaak, R. Simon, R. Knuechel, C. Pilarsky, and A. Hartmann Gene Expression Profiling of Progressive Papillary Noninvasive Carcinomas of the Urinary Bladder Clin. Cancer Res., June 15, 2005; 11(12): 4415 - 4429. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 U. H. Frey, A. Eisenhardt, G. Lummen, H. Rubben, K.-H. Jockel, K. W. Schmid, and W. Siffert The T393C Polymorphism of the G{alpha}s Gene (GNAS1) Is a Novel Prognostic Marker in Bladder Cancer Cancer Epidemiol. Biomarkers Prev., April 1, 2005; 14(4): 871 - 877. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. J. Goebell, S. Groshen, B. J. Schmitz-Drager, R. Sylvester, M. Kogevinas, N. Malats, G. Sauter, H. B. Grossman, C. P.N. Dinney, F. Waldman, et al. Concepts for Banking Tissue in Urologic Oncology--The International Bladder Cancer Bank Clin. Cancer Res., January 15, 2005; 11(2): 413 - 415. [Full Text] [PDF]
|
|
|
|
|
|
Y. Yamamoto, H. Matsuyama, T. Furuya, A. Oga, S. Yoshihiro, M. Okuda, S. Kawauchi, K. Sasaki, and K. Naito Centrosome Hyperamplification Predicts Progression and Tumor Recurrence in Bladder Cancer Clin. Cancer Res., October 1, 2004; 10(19): 6449 - 6455. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K. Kawamura, H. Izumi, Z. Ma, R. Ikeda, M. Moriyama, T. Tanaka, T. Nojima, L. S. Levin, K. Fujikawa-Yamamoto, K. Suzuki, et al. Induction of Centrosome Amplification and Chromosome Instability in Human Bladder Cancer Cells by p53 Mutation and Cyclin E Overexpression Cancer Res., July 15, 2004; 64(14): 4800 - 4809. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. F. Shariat, H. Tokunaga, J. Zhou, J. Kim, G. E. Ayala, W. F. Benedict, and S. P. Lerner p53, p21, pRB, and p16 Expression Predict Clinical Outcome in Cystectomy With Bladder Cancer J. Clin. Oncol., March 15, 2004; 22(6): 1014 - 1024. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. J. Chatterjee, R. Datar, D. Youssefzadeh, B. George, P. J. Goebell, J. P. Stein, L. Young, S.-R. Shi, C. Gee, S. Groshen, et al. Combined Effects of p53, p21, and pRb Expression in the Progression of Bladder Transitional Cell Carcinoma J. Clin. Oncol., March 15, 2004; 22(6): 1007 - 1013. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A J Colquhoun and J K Mellon Epidermal growth factor receptor and bladder cancer Postgrad. Med. J., October 1, 2002; 78(924): 584 - 589. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M.-L. Lu, F. Wikman, T. F. Orntoft, E. Charytonowicz, F. Rabbani, Z. Zhang, G. Dalbagni, K. S. Pohar, G. Yu, and C. Cordon-Cardo Impact of Alterations Affecting the p53 Pathway in Bladder Cancer on Clinical Outcome, Assessed by Conventional and Array-based Methods Clin. Cancer Res., January 1, 2002; 8(1): 171 - 179. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 Y. Mori, A. Koide, K. Fuwa, H. Wanibuchi, and S. Fukushima Lack of change in the levels of liver and kidney cytochrome P-450 isozymes in p53(+/-) knockout mice treated with N-butyl-N-(4-hydroxybutyl)nitrosamine Mutagenesis, September 1, 2001; 16(5): 377 - 383. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M A Knowles What we could do now: molecular pathology of bladder cancer Mol. Pathol., August 1, 2001; 54(4): 215 - 221. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. Inoue, J. W. Slaton, T. Karashima, C. Yoshikawa, T. Shuin, P. Sweeney, R. Millikan, and C. P. N. Dinney The Prognostic Value of Angiogenesis Factor Expression for Predicting Recurrence and Metastasis of Bladder Cancer after Neoadjuvant Chemotherapy and Radical Cystectomy Clin. Cancer Res., December 1, 2000; 6(12): 4866 - 4873. [Abstract] [Full Text]
|
|
|
|
|
|
M. Migaldi, A. Sgambato, L. Garagnani, R. Ardito, P. Ferrari, Carmela De Gaetani, A. Cittadini, and G. P. Trentini Loss of p21Waf1 Expression Is a Strong Predictor of Reduced Survival in Primary Superficial Bladder Cancers Clin. Cancer Res., August 1, 2000; 6(8): 3131 - 3138. [Abstract] [Full Text]
|
|
|
|
 |
|
 M. Burchardt, T. Burchardt, A. Shabsigh, A. De La Taille, M. C. Benson, and I. Sawczuk Current Concepts in Biomarker Technology for Bladder Cancers Clin. Chem., May 1, 2000; 46(5): 595 - 605. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
L. M. McShane, R. Aamodt, C. Cordon-Cardo, R. Cote, D. Faraggi, Y. Fradet, H. B. Grossman, A. Peng, S. E. Taube, F. M. Waldman, et al. Reproducibility of p53 Immunohistochemistry in Bladder Tumors Clin. Cancer Res., May 1, 2000; 6(5): 1854 - 1864. [Abstract] [Full Text]
|
|
|
|
|
|
H. LaRue, P. Allard, M. Simoneau, C. Normand, C. Pfister, L. Moore, F. Meyer, B. Tetu, and Y. Fradet P53 point mutations in initial superficial bladder cancer occur only in tumors from current or recent cigarette smokers Carcinogenesis, January 1, 2000; 21(1): 101 - 106. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. Pfister, L. Moore, P. Allard, H. Larue, L. Lacombe, B. Tetu, F. Meyer, and Y. Fradet Predictive Value of Cell Cycle Markers p53, MDM2, p21, and Ki-67 in Superficial Bladder Tumor Recurrence Clin. Cancer Res., December 1, 1999; 5(12): 4079 - 4084. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
L. Cheng, R. M. Neumann, A. L. Weaver, B. E. Spotts, and D. G. Bostwick Predicting Cancer Progression in Patients With Stage T1 Bladder Carcinoma J. Clin. Oncol., October 1, 1999; 17(10): 3182 - 3187. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
I. Osman, M. Drobnjak, M. Fazzari, J. Ferrara, H. I. Scher, and C. Cordon-Cardo Inactivation of the p53 Pathway in Prostate Cancer: Impact on Tumor Progression Clin. Cancer Res., August 1, 1999; 5(8): 2082 - 2088. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Sgambato, M. Migaldi, B. Faraglia, L. Garagnani, G. Romano, C. De Gaetani, P. Ferrari, G. Capelli, G. P. Trentini, and A. Cittadini Loss of P27Kip1 Expression Correlates with Tumor Grade and with Reduced Disease-free Survival in Primary Superficial Bladder Cancers Cancer Res., July 1, 1999; 59(13): 3245 - 3250. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 I. Orlow, H. LaRue, I. Osman, L. Lacombe, L. Moore, F. Rabbani, F. Meyer, Y. Fradet, and C. Cordon-Cardo Deletions of the INK4A Gene in Superficial Bladder Tumors : Association with Recurrence Am. J. Pathol., July 1, 1999; 155(1): 105 - 113. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 E. Perz and J. G. Kuhn Review : p53 in the pathogenesis, diagnosis, and treatment of cancer Journal of Oncology Pharmacy Practice, June 1, 1998; 4(2): 75 - 102. [Abstract] [PDF]
|
|
|
|
 |
|
 I. Cordone, S. Masi, F. R. Mauro, S. Soddu, O. Morsilli, T. Valentini, M. L. Vegna, C. Guglielmi, F. Mancini, S. Giuliacci, et al. p53 Expression in B-Cell Chronic Lymphocytic Leukemia: A Marker of Disease Progression and Poor Prognosis Blood, June 1, 1998; 91(11): 4342 - 4349. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 T. R. Yeager, S. DeVries, D. F. Jarrard, C. Kao, S. Y. Nakada, T. D. Moon, R. Bruskewitz, W. M. Stadler, L. F. Meisner, K. W. Gilchrist, et al. Overcoming cellular senescence in human cancer pathogenesis Genes & Dev., January 15, 1998; 12(2): 163 - 174. [Abstract] [Full Text]
|
|
|
|
 |
|
 A. Ichikawa, T. Kinoshita, T. Watanabe, H. Kato, H. Nagai, K. Tsushita, H. Saito, and T. Hotta Mutations of the p53 Gene as a Prognostic Factor in Aggressive B-Cell Lymphoma N. Engl. J. Med., August 21, 1997; 337(8): 529 - 534. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. Esrig, D. Elmajian, S. Groshen, J. A. Freeman, J. P. Stein, S.-C. Chen, P. W. Nichols, D. G. Skinner, P. A. Jones, and R. J. Cote Accumulation of Nuclear p53 and Tumor Progression in Bladder Cancer N. Engl. J. Med., November 10, 1994; 331(19): 1259 - 1264. [Abstract] [Full Text]
|
|
|
|
|
|
R. H. Hruban, P. van der Riet, Y. S. Erozan, and D. Sidransky Molecular Biology and the Early Detection of Carcinoma of the Bladder -- The Case of Hubert H. Humphrey N. Engl. J. Med., May 5, 1994; 330(18): 1276 - 1278. [Full Text]
|
|
|
|
|
|
H. P. Rutz, R. O. Mirimanoff, C. Bokemeyer, M. A. Kuczyk, J. Sehrt, M. Muller, M. Volkmann, H. Zentgraf, and P. R. Galle Clinical Implications of the p53 Tumor-Suppressor Gene N. Engl. J. Med., March 24, 1994; 330(12): 864 - 865. [Full Text]
|
|